Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prolaction and prostate cancer

W E Farnsworth, M J Gonder

    Urology
    |July 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Levodopa (L-dopa), a prolactin inhibitor, showed significant benefits for advanced prostate cancer patients. Many experienced reduced bone pain and improved mobility, with normalized acid phosphatase levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Immunosuppression by seminal plasma.

    Immunology today·2014
    Same author

    Estrogen in the etiopathogenesis of BPH.

    The Prostate·1999
    Same author

    Prostate stroma: physiology.

    The Prostate·1999
    Same author

    Figuring out why we breathe.

    Medical hypotheses·1997
    Same author

    Roles of estrogen and SHBG in prostate physiology.

    The Prostate·1996
    Same author

    TRH: mediator of prolactin in the prostate?

    Medical hypotheses·1993
    Same journal

    Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

    Urology·2026
    Same journal

    Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

    Urology·2026
    Same journal

    Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.

    Urology·2026
    Same journal

    Intractable Epistaxis and Severe Hypertension in a Young Woman.

    Urology·2026
    Same journal

    A 53-Year-Old Man with Elevated PSA and a Cystic Pelvic Lesion.

    Urology·2026
    Same journal

    Low-Grade, Papillary Bladder Tumors A plea for in-office fulguration.

    Urology·2026
    See all related articles

    Area of Science:

    • Oncology
    • Endocrinology

    Background:

    • Advanced prostate cancer (Stage D) often presents with bone pain and reduced mobility.
    • Patients refractory to conventional treatments require novel therapeutic approaches.

    Purpose of the Study:

    • To evaluate the efficacy of levodopa (L-dopa) in treating Stage D prostate carcinoma.
    • To assess L-dopa's impact on pain, mobility, and acid phosphatase levels in refractory patients.

    Main Methods:

    • Eleven patients with Stage D prostate carcinoma, resistant to standard therapies, were treated with levodopa (L-dopa).
    • Patient outcomes were assessed based on relief of bone pain, recovery of mobility, and changes in acid phosphatase levels.

    Main Results:

    • Excellent or fair relief of bone pain and improved mobility was observed in 8 out of 11 patients.

    Related Experiment Videos

  • Acid phosphatase levels, initially elevated, normalized in all patients assessed.
  • Two patients showed no improvement in symptoms.

    • Conclusions:

    • Levodopa (L-dopa) demonstrates potential as an effective treatment for advanced prostate carcinoma, particularly in managing pain and improving mobility.
    • Further research is warranted to explore L-dopa's mechanism and optimize its use in prostate cancer therapy.